期刊文献+

如何从药师成长为心血管专业临床药师 被引量:2

How to be a Clinical Pharmacist fiom a General Pharmacist in Department of Cardiology
暂未订购
导出
摘要 目的:探讨如何从普通的药师成长为心血管专业临床药师。方法:根据笔者的临床药师工作实践及临床药师药学带教经验进行分析总结。结果:从药师成长为心血管专业临床药师必须做到:根据临床需要,采用科学的学习方法,从而具备临床药师所需的基本素质,并坚持临床实践。结论:临床药师只有不断提高自身素质加强临床实践,才能在促进合理用药、保证患者用药安全方面发挥作用。 Objective: To discusss how to be a clinical pharmacist from a general pharmacist in Department of Cardiology. Mothods: Data were analyzed and summarized according to the author's clinical practice and teaching experience. Results: To be a cardiovascular professional pharmacist, one should keep on clinical practice by using scientific methods, so that one can have the basic ability of a clinical pharmacist. Conclusions: A clinical pharmacist will play an important role in promoting rational administration and guaranteeing medication safety only through improving his ability continuously and strengthening clinical practice.
作者 牟燕
出处 《药品评价》 CAS 2010年第16期51-54,共4页 Drug Evaluation
关键词 临床药师 心血管 Clinical pharmacist Department of cardiology
  • 相关文献

同被引文献27

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1408
  • 2陈秋琴,吴慧英,苏丹.临床药师在药物治疗中的作用[J].中国医院药学杂志,2007,27(2):272-273. 被引量:37
  • 3张海英,张斌,李玉珍.华法林的相互作用及其安全应用[J].药物不良反应杂志,2007,9(2):112-116. 被引量:65
  • 4Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythan management and slroke prevention: the Anticoagulation and Risk Factors In Aria1 Fibrillation (ATRIA) study [J]. JAMA 2001: 285:2370 -5.
  • 5Miyasaka Y,, Barnes ME, Gersh B J, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence [J]. Circulation 2006,114(2): 119 -25.
  • 6Fuster V, Ryden LE, Cannon DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation-Executive Summary[J]. Ciculation,2006,14(7):700-752.
  • 7European Heart Rhythm Association et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) [J].Eur Heart J. 2010,31(19):236%429.
  • 8Fihn SD, McDonell M, Matin D, et al. Risk Factors for Complications of Chronic Anticoagulation: A Mulficenter study. Warfarin Optimized Outpatient Follow-up Study Group. [J].Ann Inter Med,1993,118(7):511-20.
  • 9Perzbom E, Roehrig S, Straub A, et al. Rivaroxaban: A New Oral Factor Xa Inhibitor [J]. Artorioscler Thromb Vasc Biol,2010,30(3):376-81.
  • 10Kubitza D, Becka M, Wensing G et al. Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing ha healthy male subjects[J]. Eur J Clin Phannacol, 2005,61(12):873-80.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部